Philip Morris International Inc. (PM) Stock News

JPMorgan Chase reported Q3 2026 net income of $15.3 billion on $50.9 billion revenue. The bank is prioritizing organic growth over share buybacks, deploying AI tools internally while restricting external agents for security, and projects $107 billion in 2027 net interest income. Management highlights consumer resilience and steady execution across market conditions.

JPMorgan Chase's Q3 earnings missed expectations with EPS of $5.57 versus $5.93 expected and revenue of $50.17 billion versus $51.23 billion anticipated. CEO Jamie Dimon warned of multiple economic headwinds including large fiscal deficits, sticky inflation, elevated asset prices, rising interest rates, and geopolitical tensions that could impact the bank and economy. While market activity remains strong, particularly from AI spending, Dimon noted activity was already moderating in Q3.

Iraq parliament approves remaining cabinet posts, PM deputies  Reuters

Houthis attack presidential palace complex in Yemen's Aden, PM unharmed, officials say  Reuters

JPMorgan Chase raised its dividend for the 16th consecutive year with a 10% increase to $1.65 per share and authorized a $50 billion share repurchase program. The bank's fortress balance sheet, featuring a CET1 ratio of 14.1% (well above the 11.5% Fed requirement), provides significant excess capital to support continued dividend growth through 2027. With a conservative 27% payout ratio and a history of maintaining dividends even during the COVID crash, JPMorgan Chase is well-positioned to increase its dividend for a 17th consecutive year.

Major U.S. banks kick off Q3 earnings season with expectations for up to 20% earnings growth. However, surging Treasury yields to multi-decade highs have pressured bank shares, with the KBW Bank Index down 13% from August peaks. Investors will scrutinize impacts on dealmaking, lending growth, and funding costs amid volatile bond markets and global economic uncertainties.

Details of UK PM Burnham's Manchester City meetings published  Reuters

UK PM Burnham says Iran's IRGC likely behind RAF Fairford incident  Reuters

JPMorgan Chase's Q3 earnings report could trigger a stock decline due to rising bond yields pressuring bank stocks. While the bank expects solid investment banking and trading revenue growth in the mid-to-high teens, investors have set a high bar and may react negatively to any missed estimates, weakened guidance, or signs of deteriorating credit quality. Rising yields increase funding costs and borrowing expenses, potentially slowing lending and investment banking activity.

Zacks Research Daily features analysis of 16 major stocks including JPMorgan Chase, ASML, and Chevron, plus two microcap stocks. JPMorgan benefits from strong earnings and diversified revenues; ASML faces balanced opportunities and risks from AI demand; Chevron shows strong production growth and cash flow. Additional coverage includes Pfizer, Valero Energy, and Constellation Energy, with mixed outlooks across sectors.

Portugal PM cautions judiciary not to get political over US use of air base  Reuters

JPMorgan Chase stock has significantly outperformed the S&P 500 under CEO Jamie Dimon's 20+ year tenure. A $10,000 investment made when Dimon became CEO in 2006 would be worth approximately $83,020 today (730% gain), compared to $62,420 for the S&P 500 (524% gain). Including dividends, JPMorgan's total return reaches 1,320%, turning the initial investment into $141,540. Dimon plans to remain CEO for several more years.

J.P. Morgan Asset Management announced final September 2026 cash distributions for three JPMorgan ETFs trading on the Toronto Stock Exchange. Unitholders of record on October 19, 2026 will receive distributions on October 23, 2026, with per-unit payouts ranging from $0.0747 to $0.0942 across the three funds, all maintaining monthly payment frequency.

SPMD, a passively managed mid-cap blend ETF with $18.23 billion in assets, offers broad exposure to mid-cap companies with an extremely low expense ratio of 0.03%. The fund has gained 11.54% year-to-date and 12.4% over the past year, with heavy allocation to Industrials (23.4%), Information Technology, and Financials sectors. It received a Zacks ETF Rank of 1 (Strong Buy) and is positioned as an excellent option for long-term investors seeking diversified mid-cap exposure.

JPMorgan Chase CEO Jamie Dimon warned that cybersecurity risks have increased 10-fold following the release of Anthropic's advanced Claude Mythos AI model, which has capabilities including multi-step reasoning and the ability to penetrate advanced cybersecurity systems. While not in panic mode, Dimon emphasized the need to address these emerging AI-related threats seriously.

Q3 2026 earnings season shows strong broad-based growth with S&P 500 earnings expected to increase 24.6% on 11.5% higher revenues. Tech sector leaders Micron and Nvidia continue driving growth. However, bank stocks including JPMorgan, Citigroup, and Wells Fargo face headwinds from spiking Treasury yields, which negatively impact bond portfolios, net interest margins, and credit demand despite generally favorable earnings estimates.

JPMorgan Chase is expected to report Q3 2026 earnings on October 13 with consensus estimates of $5.94 EPS (up 17.2% YoY) and $52.21B in revenues (up 12.5% YoY). The stock has a positive Earnings ESP of +1.19% with a Zacks Rank #3, suggesting a likely earnings beat. The company has beaten consensus estimates in all four of the last quarters.

UK PM weighs delay to roadmap for higher defence spending, Times reports  Reuters

Spain's gambler PM Sanchez seeks to defy the odds again on a snap election  Reuters

Prime Medicine announced the first patient dosing in its Phase 1/2 clinical trial of PM577a, an in vivo Prime Editor therapy for H1069Q-mutated Wilson disease. The FDA granted Rare Pediatric Disease designation to PM577, and the company expects initial clinical data in 2027. PM577a is designed as a one-time curative therapy targeting the most prevalent Wilson disease-causing mutation in North America and Europe.

JPMorgan Diversified Return U.S. Equity ETF (JPUS) offers broad exposure to large cap blend stocks with a low 0.18% expense ratio and 2.07% dividend yield. The ETF has gained 12.29% year-to-date and carries a Zacks ETF Rank of 3 (Hold). However, competitors like Vanguard 500 Index Fund and iShares Core S&P 500 ETF offer lower expense ratios of 0.03% and significantly larger asset bases.

JPMorgan Chase has promoted Doug Petno and Troy Rohrbaugh to co-presidents as part of succession planning for CEO Jamie Dimon's eventual retirement. The move signals intense internal competition for the top role, with high-level executive Marianne Lake departing around the same time. While the new CEO will likely be highly skilled, the succession process may result in brain drain as losing candidates and other top talent seek opportunities elsewhere.

Natera announced that its Signatera test received regulatory approval from Japan's PMDA as a companion diagnostic for muscle-invasive bladder cancer (MIBC), supporting Signatera-guided adjuvant atezolizumab treatment decisions. The approval, supported by IMvigor011 Phase III trial data, marks the company's second PMDA authorization in three months. Commercial launch in Japan is planned for H1 2027. The stock gained 5.5% following the announcement.

JPMorgan Chase & Co. (JPM) closed down 3.34% in the latest trading session, underperforming the broader market. The stock has declined 1.22% over the past month. Analysts expect the company to report Q3 earnings of $5.84 per share (up 15.19% YoY) and revenue of $51.5 billion (up 10.92% YoY) when earnings are disclosed on October 13, 2026. JPM currently holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 14.11, trading at a slight premium to its industry average.

The Federal Reserve's 25 basis point rate hike to 3.75-4.00% is expected to provide modest benefits to JPMorgan's net interest income through higher loan yields, supported by 10% average loan growth and 7% deposit growth in Q2. However, gains may be limited by increased deposit costs, softer loan demand, and rising credit costs. Peers Bank of America and Citigroup are similarly positioned to benefit, though facing comparable headwinds.

JPMorgan Chase CEO Jamie Dimon warns that retirement is becoming unattainable for many Americans. The average person believes they need $1.2-1.4 million to retire comfortably, but median retirement savings for those aged 56-74 are only $185,000-$200,000. Additionally, 67% of small business owners lack succession plans, with 27% planning to shut down when they retire. This retirement wave could significantly impact the U.S. economy as Main Street businesses close and wealth inequality widens.

Zacks Market Edge Podcast celebrates its 500th episode by revisiting investment lessons from 11 years of market coverage. The podcast highlights three large-cap stocks recommended in the 300th episode (2022) that have remained relevant in 2026: ExxonMobil, JPMorgan Chase, and NVIDIA. All three have significantly outperformed the S&P 500 over the past 5 years, with NVIDIA showing exceptional growth driven by the AI Revolution. The article emphasizes the investing principle of not overcomplicating stock selection and focusing on obvious, quality large-cap opportunities.

The Invesco S&P MidCap 400 GARP ETF (GRPM) is a smart beta ETF with $492.42 million in assets that seeks to track mid-cap companies with consistent growth, reasonable valuation, and strong earnings. With a 0.35% expense ratio and year-to-date performance of 15.89%, it offers diversified exposure across 63 holdings led by Abercrombie & Fitch, Hecla Mining, and Duolingo. Alternative options include Vanguard Morningstar Mid-Cap ETF (VO) and iShares Core S&P Mid-Cap ETF (IJH), which offer lower expense ratios.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Novartis's Cosentyx (secukinumab) for treating polymyalgia rheumatica (PMR) in adults. If approved, it would be the first IL-17A inhibitor licensed in Europe for PMR, offering an alternative to long-term steroid therapy. The recommendation is based on Phase III REPLENISH trial data showing Cosentyx doubled sustained remission rates and provided steroid-sparing effects compared to placebo, with a safety profile consistent with its established use in other autoimmune diseases.

Zacks presents its Focus List investment strategy, which selects 50 stocks expected to outperform the market over 12 months based on earnings estimate revisions. The article highlights JPMorgan Chase as a Focus List example, noting its 412.86% gain since October 2016 addition. The Zacks Rank system, which has outperformed the S&P 500 by an average of +23.80% annually since 1988, uses four pillars (Agreement, Magnitude, Upside, and Surprise) to classify stocks from Strong Buy to Strong Sell.